Generics Erosion Patterns in the U.S. Market : Market Research Report

Generics Erosion Patterns in the U.S. Market

Published: Apr. 3, 2007 - 22 Pages

The price of this report has been reduced due to its age. The original price was $2,025 for PDF.

Executive Summary: Strategic Considerations; Stakeholder Implications
Introduction
Methodology
Factors Infl uencing Generics Erosion
Exceptions to Traditional Generics Erosion Patterns
Patterns of Generics Erosion by Formulation: Oral Solids; Group 1; Group 2; Group 3; Oral Liquids and Other Formulations (Nasal, Ophthalmic Liquids, Patches/Discs); Injectables
Other Findings: Comparison of Average Oral Solid Generics Erosion; Market Infl uence of Generics Manufacturers; Price As a Factor
Will These Patterns Continue?
Tables: 1. Drugs and Formualtions Examined in this Report; 2. Defi nitions and Parameters of Drug Groupings in this Report
Figures: 1. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 1; 2. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 2; 3. Generics Erosion for Selected Products, 2002-2006: Oral Solids, Group 3; 4. Generics Erosion for Selected Products, 2002-2006: Oral Liquids; 5. Generics Erosion for Selected Products, 2002-2006: Other Formulations; 6. Comparison of Average Generics Erosion (by Formulation) for Five Drugs; 7. Generics Erosion for Selected Products, 2002-2006: Injectables/IVs; 8. Average Generics Erosion Rates of Oral Solids, 2002-2006; 9. Estimated Average Number of Generics Competitors by Formulation; 10. The Effect of Generics Manufacturers on Brand Market Share Volume; 11. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Zithromax; 12. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Lotensin; 13. How Brand Manufacturers Can Maintain Total Prescription Share Through Generics Subsidiaries: Celexa

Abstract

With an estimated $51 billion of branded drugs coming off patent between 2006 and 2011, both U.S. government insurance plans and private, third-party payers will promote increased use of generics in the future. In a data-rich report that employs analyses of 34 branded drugs facing generics competition between January 2002 and December 2006, we highlight the most effective strategies employed by pharmaceutical companies in their effort to ward off the threat of generics competition.

Get the Answers You Need to Shape Your Strategy:

Several factors determine how quickly a branded product loses market share. Which of these factors is particularly likely to lead to big paydays for generics manufacturers? Under what circumstances can the effects of this critical factor be muted?
After Zithromax lost patent protection in the United States, Pfizer entered the generics market for Zithromax through its own generics subsidiary. How successfully did Pfi zer’s subsidiary fend off erosion of prescription share for Zithromax? What lessons can other drug companies take away from Pfizer’s strategy?
Merck employed an unusual pricing strategy in order to retain its market share for Zocor, after generics entered the market for the branded product. How successful was Merck in delaying erosion of Zocor’s market share?
Oral solids typically experience generics erosion at a different rate than other drug formulations (oral liquids, nasal products, and patches). What factors account for this difference?

Get Full Details About This Report >>

US: 800.298.5699

Int'l: +1.240.747.3093

About MarketResearch.com
MarketResearch.com is an online aggregator selling over 160,000 market research reports, company profiles and country profiles from over 600 research firms. Our reports will provide you with the critical business and competitive intelligence you need for strategic planning and marketing research. Coverage includes the US, UK, Europe, Asia and global markets.

Generics Erosion Patterns in the U.S. Market

Table of Contents

Abstract